ABOUT

Zydus Cadila is headquartered in Ahmedabad, India, and ranks 4th in the

Indian pharmaceutical industry. The group has manufacturing sites and research
facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh
and Sikkim in India and in the US and Brazil. Zydus’ global business has a strong
presence in the regulated markets of the US, Europe (France and Spain) and in the
high profile markets of Latin America and South Africa. It is also present in a big way
in 25 other emerging markets worldwide.  Zydus Cadila, a leading Indian
Pharmaceutical company is a fully integrated, global healthcare provider. With in-
depth domain expertise in the field of healthcare, it has strong capabilities across the
spectrum of the pharmaceutical value chain. From formulations to active
pharmaceutical ingredients and animal healthcare products to wellness products,
Zydus has earned a reputation amongst Indian pharmaceutical companies for
providing comprehensive and complete healthcare solutions.
The origin of the company dates all the way back to the 1950s. The company
was founded in the year 1952 by Mr. Ramanbhai B. Patel (late). In 1995, the group
was restructured and thus was formed Cadila Healthcare under the aegis of the
Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a
significant financial growth and registered a turnover of over Rs. 14,253 crores in
FY20.
Zydus continues to innovate with an unswerving focus to address the unmet
healthcare needs. Simultaneously it rededicates itself to its mission of creating
healthier, happier communities across the globe.
MISSION AND VISION

IN THE COMMUNITY

Good health, happiness, joy, growth, togetherness, discovery, learning, exploration,

evolution, transformation, aspirations, are all intrinsically linked with life. Zydus is
dedicated to all these dimensions. Zydus Srishti, the group’s CSR programme, is
about reaching out to make a difference in a myriad ways in the areas of Health –
Swaasthya, Education – Shiksha, Research – Shodh and Outreach – Saath.
Through these initiatives, the group reaches out to the community that it forms a part
of, finding new expressions for its mission to create healthier communities globally.
Ethical practices, accountability, robust governance and sustainable initiatives are at
the very core of the group’s business strategy, planning and operations which helps
minimise risks and leverage opportunities to create value. The group’s philosophy for
community engagement is based on the principle of volunteerism and is an
intensive, comprehensive and sustainable programme.

Swasthya: Health Safety & Environment

 Rural health awareness camps
 Promoting preventive health care
 De-addiction camps
 Personal hygiene camps
 Maternal healthcare programmes
 Sanitation – making available safe drinking water
 Support to hospitals and primary healthcare centres
 Ensuring environmental sustainability through maintenance of soil, air and
water
Shiksha: Education
 Support to the Zydus School for Excellence
 Community initiatives undertaken by the students of the school
 Adopting primary schools
 Awards and recognition for school children in the rural areas around our
manufacturing facilities
 Educational programmes for farmers in the rural areas around our
manufacturing facilities
 Infrastructure support to primary schools
 Sponsorships extended to The Ahmedabad Management Association, Indian
Pharmaceutical Association etc. through the Ramanbhai Foundation

Shodh: Research
 Promoting research in pharmaceuticals and healthcare through the biennial
symposium, The Ramanbhai Foundation International which brings together the
scientific community from across the world, both from academia and industry
who deliberate upon unmet medical needs, new research initiatives and some
latest advancements in healthcare and medical science.

HUMAN RESOURCES
Building people capabilities and providing them platforms and opportunities to
grow and spread their wings has always been a unique strength of the organisation.
An essential part of Zydus value proposition is ‘GROW’, which looks at Global
opportunities; Respect, recognition, care and building talent from within;
Opportunities across the value chain and Working with the best. Zydus build People
to Build the Business – was the motto since 1995, and the HR team has been
focusing its efforts on this ethos at every step of the journey as they grew into a
multi-locational, innovation-driven global healthcare company.
During the year, the HR initiatives have focussed on –

Talent management:
In keeping with the changing business and technological landscape, a
technical competency framework has been built for the teams driving innovation,
operations and the commercial cluster. This framework is being used for hiring talent
and developing internal talent. A customised framework for the marketing team has
also been created, as a part of which all product managers and brand manager will
undergo a brand building competency programme.

Talent pool:
A group of young and prospective leaders were taken through a structured
leadership development programme called LEAP in which business objectives were
linked to their individual roles and career development and business projects were
linked to their individual development based on leadership competencies.
Manufacturing excellence:
For the manufacturing teams, the Company has mapped critical processes,
machines and the expected levels to drive productivity and performance. Hiring
guidelines have been created for all the critical products based on critical machine
and processes. Skills matrix has been mapped for all manufacturing employees and
the development journey for skills development is underway. As a part of the
capability building initiatives, FTEs are being enrolled for customised education
programmes.

Driving sales force effectiveness and efficiency:

Critical high productive headquarters have been mapped, and customised
engagement programmes are being driven for higher productivity and sustainability.

Mission to Institutionalise Excellence in Leadership, Execution and

Strategy (MILES):
Corporate manufacturing and quality leadership teams are working on
developing the next level of quality and excellence culture in the organisation.
ZCLOM: Zydus Collaborative Leadership Operating Model (ZCLOM) is an initiative
aimed at creating a culture of collaboration, trust and positivity by focusing on peer-
based strengths which will eventually define the ‘Leadership Culture’ of the Company

INDIA BUSINESS
 The India Business comprises the India formulations business spearheaded
by Zydus Healthcare Ltd., based in Mumbai and the Biologics business which drives
the sales and marketing of biosimilars and novel biologics. Zydus Healthcare Ltd.
Zydus is one of the oldest players in the Indian formulations market and has gone
onto become a prominent pharmaceutical manufacturer in India. Besides
continuously improving its market presence and market share, the group has also
expanded its portfolio by entering newer therapeutic areas.The group has been
launching new products with the first mover advantage and has a strong presence in
both acute and chronic therapies.
These strategic initiatives have helped Zydus become one of the dominant
players in the Indian formulations market with the leadership position in several
therapeutic categories. The group’s innovative NCE therapy Lipaglyn, a novel drug
to be approved for the treatment of diabetic dyslipidemia is marketed by Zydus
Discovery, a division of Zydus Healthcare Ltd.

Zydus Biologics and Vaccine Development

Zydus Biologics, a super-specialty centric business entity of Cadila
healthcare Ltd., is engaged in manufacturing and commercialization of both, small
molecule, biological drugs and vaccines intended for prevention and treatment of
various diseases in the field of oncology, hepatology, nephrology, rheumatology,
ophthalmology and bone health. With capabilities across the value chain - Drug
development, manufacturing, distribution and commercialization, Zydus Biologics
has emerged as one of the leading players in the biologics market and has a
formidable presence in its participatory market. Zydus Biologics' developmental
capabilities cover fusion proteins, monoclonal antibodies, antibody drug conjugates
and vaccines. It has a robust pipeline comprising of next generation biosimilars, and
novel biologicals. As part of its vision of being at the forefront of innovation led
growth, Zydus Biologics has undertaken several pioneering initiatives like launching
Exemptia, world's first biosimilar of Adalimumab, Vaxiflu S - Indian's first
indigenously developed H1N1 vaccine for protection against swine flu, Vaxiflu 4 -
India's first quadrivalent influenza vaccine and ZyVac TCV – World’s second brand
of typhoid conjugate vaccine.In line with the group’s endeavour to improve access to
healthcare for the public at large, Zydus Biologics has initiated various
developmental programmes in the vaccines and diagnostics space. The aim is to
cater to unmet needs of the people of this country in the field of immunization and
detection of rare infectious diseases. Vaccine Technology Centre of Zydus Cadila
has wide range of capabilities in developing and manufacturing viral, toxoid,
polysaccharide, conjugate and other subunit vaccines for unmet needs. In fact,
Zydus was the first company in India to develop and indigenously manufacture the
vaccine to combat Swine Flu during the pandemic in 2010. In past, it has also
indigenously developed numerous vaccines successfully including tetravalent
seasonal influenza vaccine (first company in India to indigenously develop and
commercialize), Inactivated Rabies vaccine (WHO Prequalified), Varicella vaccine
(first Indian company to indigenously develop and receive market authorization),
Measles containing vaccines (MR, MMR, Measles), Typhoid conjugate vaccine,
pentavalent vaccine (DPT-HepB-Hib) etc to name a few. The company also has a
strong pipeline of vaccines like Measles-Mumps-Rubella-Varicella (MMRV), Human
papillomavirus vaccine, Hepatitis A, Hepatitis E vaccines which are at various stages
of development.

COVID-19 vaccine development

In February 2020, in a press release, the company announced the launch of

developing a potential COVID-19 DNA based vaccine from a live attenuated
recombinant measles virus vectored vaccine to combat the virus. In July 2020, the
company got permission to conduct human trials of the developmental COVID-19
vaccine named ZyCoV-D, from the Drugs Controller General of India (DCGI),
Government of India. Zydus is also among the several Indian pharma companies
that received the licensing agreements from the Gilead Sciences to produce
remdesivir.

The Company reports that the doses of the vaccine administered to healthy
volunteers in the Phase I clinical trial, which began on 15th July 2020, has been well
tolerated. Previously, the vaccine was found to be safe, immunogenic and well
tolerated in the pre-clinical toxicity studies. The vaccine was able to elicit high level
of neutralizing antibodies in animal studies.

The company has commenced Phase II clinical trials from the 6 th of August, 2020.